Azacitidine
Azacitidine
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Azacitidine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPEGINTERFERON ALFA-2B M.D. Anderson Cancer Center | Phase 1/2 | CC |
Venetoclax Henan Cancer Hospital | N/A | D |
INTERFERON ALPHA 1B Henan Cancer Hospital | N/A | D |
Thalidomide Henan Cancer Hospital | N/A | D |
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →